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Abstract 
 
This study tested a three-item questionnaire of global quality of life (QOL) and pain in 
patients commencing radiotherapy, based on items from the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 instrument. In pre-test, the 
EORTC QLQ-C30 and the three-item short questionnaire were administered to 100 
patients, yielding similar global QOL and pain scores. After the pre-test, the three-item 
questionnaire was administered to 1,837 patients prior to first radiotherapy treatment.  
We identified 254 (13.8%) patients with impaired QOL. These patients had a mean 
global QOL score of 32.6 compared to 72.4  (p<0.001) found in patients with 
satisfactory QOL. Patients with impaired QOL were also more likely younger than 60 
years and treated for lung, gastrointestinal or head & neck cancer or advanced, 
metastatic cancer. 
This brief instrument addresses important aspects of quality of life, is feasible to use in 
a clinical setting and therefore represents a potentially useful tool for detecting those 
patients who may benefit from further evaluation and/or psychosocial support. 
 
Key Words: cancer, radiotherapy, quality of life, screening, psychosocial support. 
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Zusammenfassung: 
Im Rahmen dieser Studie wurde ein Kurzfragebogen zur Erfassung der Lebensqualität 
basierend auf dem Lebensqualitätfragebogen der European Organization for Research 
and Treatment of Cancer (EORTC) QLQ-C30 entwickelt. In einer Pilotstudie wurden 
100 Patienten randomisiert der EORTC-QLQ C30 und der 3-Fragen Kurzfragebogen 
vor Beginn der Bestrahlung vorgegeben. Beide Fragebögen erbrachten einander 
entsprechende Werte für die allgemeine Lebensqualität und das derzeitige 
Schmerzniveau der Patienten (Tabelle 1). Im Anschluß an diese Pilotstudie wurde der 
Kurzfragebogen 1837 Patienten vorgegeben. Patientencharakteristika finden sich in 
Tabelle 2 und 3.  
Wir erfaßten 254 (13,8%) der Patienten welche unter einer beeinträchtigten 
Lebensqualität bereits vor Beginn der Bestrahlung litten. Diese Patienten hatten einen 
mittleren globalen Lebensqualitätswert von 32,6 im Vergleich zu 72,4 (p<0.001), 
welcher bei Patienten mit zufriedenstellender Lebensqualität gemessen wurde. Patienten 
mit niedriger Lebensqualität waren jünger als 60 Jahre, und erhielten 
überdurchschnittlich häufig eine Behandlung wegen eines Bronchialkarzinoms, colo-
rektalen Karzinoms, Kopf-Hals Tumors oder palliative Behandlung (Tabelle 2). Die 
Lebensqualitätswerte, die in der vorliegenden Stichprobe gemessen wurden, wurden 
weiterhin mit Normen, welche für die deutsche Bevölkerung für den EORTC-QLQ C30 
vorliegen, verglichen (Abbildung 1a und 1b). 
Der kurze Lebensqualitätsfragebogen, der hier präsentiert wurde, misst wichtige 
Aspekte der Lebensqualität, ist anwendbar auch in der arbeitsreichen Atmosphäre einer 
Tagesklinik, und könnte sich daher als wichtiges Screening-Instrument der 
Lebensqualität für die Strahlentherapie erweisen. Patienten mit schlechter 
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Lebensqualität am Beginn der Bestrahlung könnten in besonderem Ausmaß von 
zusätzlicher Betreuung und/oder Information profitieren.   
 
 
Key Words: Krebs, Strahlentherapie, Lebensqualität, Screening, Psychosoziale 
Unterstützung.  
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Introduction 
Diagnoses and treatments of cancer frequently impose significant burdens on patients. 
Quality of life (QOL) is affected by the diagnosis itself [22] as well as the diagnostic 
procedures, and often deteriorates further due to treatment-related side effects [7,14]. 
Patients suffer from reduced QOL and psychosocial problems even long after their 
cancer treatment has been completed [17]. QOL and psychological well-being are 
related to each other [18,27] and might predict the response to chemotherapy [16,31]. 
Early treatment of reduced quality of life and psychosocial distress could be beneficial 
for some but probably not all patients [30,31]. In a recent meta-analysis, psychological 
interventions appeared to be more effective if patients were selected for therapy rather 
than if they were just included on the basis of their cancer diagnosis [26]. Early 
psychological treatment might be especially important for patients undergoing 
radiotherapy [33], because patients are distressed before commencement of radiotherapy 
[13] and throughout treatment [24] and early intervention is effective in reducing patient 
distress [20]. However, no “gold standard” currently exists to identify patients who 
might benefit most from psychosocial or psychoeducational interventions. 
Previous reports indicate that QOL measures might carry independent prognostic 
information [2,3,6,28], but others could not confirm these results and found only pain to 
be predictive for the outcome of lung cancer patients [10]. Baseline scores from the 
European Organisation for Research and Treatment Quality of Life Questionnaire 
(EORTC QLQ-C30) and two single questions (overall physical condition, overall 
quality of life) provided independent prognostic information in a series of patients with 
advanced stages at various tumor sites [3]. Single-item scales like the Spitzer Uniscale 
were compared with other QOL tools and were shown to be equally sensitive and 
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prognostically relevant as the more time-consuming methods [28]. The EORTC QLQ-
C30 is easy to complete, however, in a hurried ambulatory setting might conflict with 
standard procedures. 
Recently, German, population-based, reference data became available for the EORTC 
QLQ-C30 [23] and showed that the general population has a far from perfect QOL [5]. 
Fayers suggested using the population based reference data as a comparison for 
patient’s scores by taking the absolute difference between the two values or computing 
a percentage reduction and to aim for QOL comparable to the general population in 
cancer patients as a minimal goal [5].  
In order to identify patients with impaired QOL in a clinical setting, we designed a 
three-item screening questionnaire based on items from the EORTC QLQ-C30 
instrument. In a pretest, patient responses to the three-item questionnaire were 
compared to the 30-item EORTC QLQ- C30 to establish comparability. It was then the 
aim of this study to test the feasibility of using the three-item questionnaire in an 
unselected group of patients commencing radiotherapy and to compare our results to 
those available in the literature [11,16,18,23,32].  
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Patients and Methods  
Patients 
All patients who were referred between August 1998 and November 1999 to the new 
patient clinic of the Radiotherapy Department of the University Hospital, Medical 
School of Vienna, were considered for this trial. Eligible patients had to meet the 
following criteria: histologically proven malignancy, age older than 18 years, first 
contact with our department, prior to receiving first radiotherapy treatment, not 
requiring constant hospital care, and able to understand German well enough to answer 
the questions. Patients were consented if they were able and willing to fill in the 
questionnaire. Due to organisational reasons we could not perform our study during 
some periods while administrative staff were on leave. Therefore only 2,026 of the 
3,581 new patients could be screened for eligibility. Twenty-one (1.0%) patients 
younger than 18 years of age and 168 (8.3%) patients who refused to participate or did 
not meet the eligibility criteria were excluded from the study. Therefore 1,837 patients 
remained eligible for analysis.  
Based on the diagnosis, each patient was managed by a team of specialized 
radiotherapists. Group one consisted of patients with breast cancer (breast), group two 
comprised women with gynaecological cancer and patients with urogenital cancer 
(GU/GYN). Group three included patients with cancer of the lung, the gastrointestinal 
tract, or head and neck cancer (Lung/GI/H&N). Group four comprised patients with 
lymphoma, leukemia (HAEM) or brain tumors. Patients were referred to group five 
mainly for the treatment of bone or skin metastases (Advanced Cancer). 
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Questionnaire 
Two items addressing overall physical condition (OPC) and overall quality of life 
(OQOL) were taken with permission from the original EORTC QLQ-C30 [21]. OPC 
and OQOL are rated on a seven-point scale ranging from 1 (very poor QPC/OQOL) to 7 
(excellent OPC/OQOL). To allow comparison with normative data, a score for global 
quality of life was computed by combining OQOL and OPC and linearly transforming 
the resulting summary score to a 0 to 100 scale with higher scores representing better 
global QOL [21]. The third item addressed pain during the last week. Item 9 from the 
original EORTC QLQ-C30 was recoded with permission from the EORTC to measure 
pain on a seven-point scale. Patients could therefore rate their current pain between 1 
(highest possible pain level) and 7 (no pain at all). This score was also transformed to a 
0-100 scale, with higher scores representing higher levels of pain. In the absence of an 
established cut-off level for impaired QOL, patients with a score of 1 or 2 in at least one 
of the three items were classified as “impaired QOL”.  
Pretest 
To test the comparability of the QOL scores derived with the short questionnaire and 
the EORTC QLQ-C30 100 consecutive patients (20 patients from each of the five 
treatment groups) completed both instruments, administered in random order (short 
questionnaire before EORTC QLQ-C30 or EORTC QLQ-C30 before short 
questionnaire). The resulting scores were compared within each treatment subgroup 
using paired-sample t-tests.  
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Data Analysis 
Chi-Square tests were conducted to compare patients’ characteristics with satisfactory 
and impaired QOL status (impaired quality of life was defined by a raw score of ≤ 2 in 
at least one of the three questionnaire items). Mean scores of global QOL and pain for 
patients with impaired and satisfactory QOL were compared using Student’s t-test. To 
investigate the independent influence of gender, age, and treatment subgroup on global 
quality of life and pain, multivariate logistic regression analyses was performed. 
Variables were collapsed using reference coding to detect those characteristics 
independently associated with impaired QOL. The Statistical package for the Social 
Sciences (Version 9, SPSS; Spss, Inc, Chicago, IL) was used for all statistical analyses. 
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Results 
The pretest revealed that the mean global QOL scores and mean pain scores measured 
by the three-item questionnaire were similar to the scores obtained when these questions 
were asked within the EORTC QLQ-C30 questionnaire (Table 1).  
In the larger study, patients’ mean age was 58 years (range: 18 to 93 years), and 65% of 
all patients were women. Overall, we identified 254 of the 1837 (13.8%) patients to 
have impaired QOL. Table 2 presents characteristics of patients with impaired and 
satisfactory QOL prior to commencement of radiotherapy. When compared to patients 
with satisfactory QOL, patients with impaired QOL were significantly more likely to be 
of younger age (17% of those 18-29 years compared to 10.3% of those >70 years 
reported impaired QOL). Significantly more men (17%) than women (12.1%) reported 
impaired QOL.  The patient groups with the highest proportion of reporting impaired 
QOL was treated for Advanced Cancer (31.4%) followed by those treated for cancer of 
the Lung/GI/H&N (17.7% with impaired QOL) (Table 2).  
The mean global QOL score was 32.6 for patients with impaired QOL and 72.4 among 
patients in this study who reported satisfactory QOL (t-value = 30.063, p<0.001). The 
mean pain score was 70.9 for patients with impaired QOL, compared to a mean score of 
18.1 for patients with satisfactory QOL (t –value = 32.9, p < 0.001). Table 3 
summarises the global QOL and pain scores for gender and treatment subgroups. Figure 
1a+b show the global QOL and pain scores for men and women by age groups in 
comparison with population-based data [19]. As expected, cancer patients, on average 
report lower global QOL and higher pain than the general population; however, for both 
men and women, there is a noteworthy cross-over at older ages and cancer patients 
actually report higher global QOL and lower pain on average. 
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Results of the multivariate logistic regression analysis to predict impaired QOL are 
presented in Table 2. Patients older than 60 years were significantly less likely to report 
impaired QOL compared to patients younger than 60 years. When adjusted for age and 
treatment subgroup, the OR for patients with both genders were similar (OR = 0.97). 
For evaluation of treatment subgroup adjusted for age and sex, patients treated for 
LUNG/GI/H&N were selected as a reference group, since men and women are equally 
represented in this treatment subgroup. In comparison, patients treated for advanced 
cancer were significantly more likely to report impaired QOL (OR = 2.4) whereas 
patients treated for breast cancer were significantly less likely to report impaired QOL 
(OR = 0.4). The remaining two treatment groups were not significantly different from 
the comparison group.  
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Discussion 
Up to 60% of all cancer patients receive radiotherapy at some stage of their illness [19]. 
For clinicians, it is obvious that a significant number of patients suffer from acute, 
impaired QOL during treatment [19], whereas others seem to improve in their QOL [22, 
8]. Research, largely in the context of chemotherapy, indicates that patients with 
impaired QOL are not only more likely to experience marked side effects during 
treatment [31], but that QOL furthermore provides independent prognostic information 
[2,3,6,16,28]. Determining QOL at baseline and addressing QOL issues during 
treatment are therefore critically important to the care of the patient. More patients than 
ever are seen in outpatient settings, where visits are short and hurried to contain costs. 
An ideal screening test for QOL should be inexpensive, easy to administer, present 
results to the medical staff immediately and should impose minimal inconvenience to 
the patient, while covering relevant aspects of the patients experience [25,9]. While 
computerised versions of the EORTC QLQ-C 30 are a promising alternative [32], costs 
related to the purchase and maintenance of the computer facilities and the specialised 
staff needed for such facilities might impose difficulties. 
In the present study, we report on the feasibility and usefulness of a very short screening 
instrument consisting of only three questions on QOL and pain based on the EORTC 
QLQ-C30 questionnaire. We demonstrated that this tool results in scores comparable to 
those derived if the questions are asked within the complete EORTC QLQ-C30 
questionnaire and is well accepted by patients and staff. Since completion of this study, 
organisational problems responsible for the intermittent screening during data collection 
have been resolved, and the ongoing screening rate is now close to 95%. Both the 
preparation time necessary to introduce patients to this three-item questionnaire and the 
refusal rate among patients are very low. Completed questionnaires can be easily 
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reviewed and a score below the proposed cut-off level can be noticed by the medical 
and psychosocial staff immediately. 
For the aim of this study, we defined a raw score of 1 or 2 in any of the three 
questionnaire items to represent impaired quality of life. Overall, the incidence of 
impaired QOL by this definition was almost 14%, which compares favourably with 
previous studies carried out using more time-consuming methods [12,21,29]. Although 
the three items are correlated with each other, they each capture distinct aspects of QOL 
(data not shown).  
In this Austrian study, the mean global QOL score was 66.9 for the whole sample. This 
is somewhat lower than the 70.8 reference value in the general German population [23], 
very close to the 65 observed in a group of English radiotherapy patients [18] and 
higher than the 52.3 reported for a mixed group of American cancer patients [32], all 
based on the EORTC QLQ-C30. The utility of these three questions as a screening tool 
is evident from the mean global QOL score of 32.6 for patients identified as having 
impaired QOL, which is significantly lower than the 72.4 among patients reporting 
satisfactory QOL. The latter score corresponds well with the mean global QOL scores 
of 77.3 and 70.8 found in general population samples from Norway [11] and Germany 
[23]. 
In the present study, patients with impaired QOL were more likely to be younger than 
60 years. In contrast, older people describe worse quality of life in the general 
population [11,23]. For example, in comparison to the population-based reference data 
from Germany [5,23], men in the age group 18-29 from our study reported a mean 
global QOL score of 70.7 compared to 83.6 from the general population sample, which 
is a reduction by 13 points. Women aged 18-29 reported a global QOL score of 64.2 in 
our study compared to 78.9 in the general population, a reduction of 14.7 points and 
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representing lower QOL levels than seen for men. Pain scores in these younger groups 
were considerable higher (representing more pain) than in the general population (e.g. 
male cancer patients aged 18-29 reported a pain score of 23.6, compared to 3.7 in the 
general population pain). However, pain scores in the older groups of cancer patients 
were somewhat lower than in the general population (e.g., women aged 60-69 reporting 
mean score of 22.6, compared to 23.9 for the general population). The QOL scores 
reported by the cancer patients older than 60 years were similar or slightly better than 
those of the general population (Figure 1). As Fayers points out, the expectation with 
which people are comparing their actual QOL might be an explanation for the relatively 
low QOL scores found in the older general population [5] compared to the cancer 
patients in the present study. Men were more likely to report impaired QOL in 
unadjusted analysis however, there was no significant difference in QOL between men 
and women in the adjusted multivariate analysis.  
Looking at the results of the multivariate modeling reveals that those patients treated for 
Lung/GI/H&N cancer, or for advanced cancer were more likely to report worse QOL 
prior to commencing radiotherapy compared to other patients. Whether clinical 
interventions or psychosocial support can improve QOL in these patients and enhance 
prognosis following radiotherapy remains unknown.  
The short screening questionnaire presented in this study will not replace existing, 
multi-dimensional QOL questionnaires in research settings or where characterization of 
QOL is a major focus. However as an aid to clinical practice, this three-item 
questionnaire offers a useful way to identify patients who may be referred for specialist, 
psychosocial support [4]. Fayers recommends “ …a modest initial target in patient 
management might be to try to ensure the patients’ QOL is no worse than the average of 
the age and gender matched population” [5, p1333]. In the future, further evaluation of 
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quality of life and psychological distress will be performed at our clinic for those 
patients identified with impaired QOL. 
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Table 1: Pretest comparison of mean global quality of life scores (± standard deviation) and mean pain scores (± standard deviation) as measured 
by the EORTC-QLQ C 30 and the three-item questionnaire by treatment subgroup 
 
 Global Quality of Life Score Pain Score 
 EORTC 
QLQ-C30  
Three-item 
questionnaire  
Paired t-
test 
p-value EORTC QLQ-
C30  
Three-item 
questionnaire  
Paired t-
test 
p-value 
Treatment Subgroup        
Breast 74.2 ± 21.6 77.5 ± 21.6 1.2 0.25 17.5 ± 21.6 18.3 ± 25.5 0.1 0.96 
GU, GYN 64.9 ± 29.4 70.8 ± 27.5 1.5 0.14 25.8 ± 33.9 17.5 ± 24.5 1.3 0.21 
Lung/GI/H&N 53.0 ± 26.1 59.0 ± 28.8 1.9 0.06 44.0 ± 35.9 43.3 ± 37.6 0.1 0.90 
HAEM/Brain 60.4 ± 27.1 60.4 ± 26.5 0.0 1.00 25.0 ± 31.3 40.0 ± 37.2 1.6 0.11 
Advanced Cancer 45.8 ± 28.7 51.7 ± 30.1 1.0 0.31 60.8 ± 44.3 55.0 ± 35.1 0.8 0.43 
Abbreviations: GU = Genitourinary Cancer, GYN = Gynaecological Cancer, GI = Gastrointestinal Cancer, H&N = Head and Neck Cancer, 
HAEM = Haematological Malignancy
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Table 2: Characteristics of patients (N=1,837) and multivariate logistic regression 
analysis of factors predicting impaired quality of life 
 Patients with 
satisfactory  QOL 
Patients with  
impaired QOL † 
Adjusted* Odds 
Ratio (95% CI) 
χ2Test 
and p-
value for 
Trend  
 N=1,583 % N= 254 %   
Age (years)  58.4  55.9   7.44, 
p=0.006 
Median 59  56    
Range 18-93  18-93    
18-29 44 2.8 9 3.5 1.65 (0.73-3.76)  
30-39 125 7.9 23 9.1 1.42 (0.81-2.47)  
40-49 229 14.5 43 16.9 1.54 (0.98-2.42)  
50-59 417 26.3 83 32.7 1.57 (1.07-2.32)  
60-69 383 24.2 52 20.5 Reference group  
>70 385 24.3 44 17.3 0.78 (0.51-1.21)  
Sex       8.3, 
p=0.004 
Men 532 33.6 109 42.9 Reference group  
Women 1051 66.4 145 57.1 0.97 (0.70-1.34)  
Treatment subgroup    48.9, 
p=0.001 
Breast 655 42.4 58 23.3 0.44 (0.28-0.67)  
GU, GYN 197 12.7 30 12.0 0.90 (0.56-1.46)  
Lung/GI/H&N 288 18.6 62 24.9 Reference group  
HAEM/Brain 273 17.7 38 15.3 0.64 (0.41-1.00)  
Advanced Cancer 133 8.6 61 24.5 2.41 (1.59-3.64)  
Missing 37 2.3 5 2.0   
Abbreviations: QOL = Quality of life, GU = Genitourinary Cancer, GYN = 
Gynaecological Cancer, GI = Gastrointestinal Cancer, H&N = Head and Neck Cancer, 
HAEM = Haematological Malignancy, Missing because of uncertainty at admission. 
* Multivatiate logistic regression analysis with all variables adjusted for all other factors 
to predict the impaired QOL at commencement of radiotherapy 
† Impaired QOL defined as a score of 1 or 2 in at least one of the three items of the 
three-item questionnaire. 
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Table 3: Mean global quality of life and mean pain scores, by gender and treatment subgroup 
 
 Treatment subgroup   Treatment subgroup   
 Men (N = 641)      Women (N = 1196)       
      All Breast GU Lung/ 
GI/ 
H&N 
HAEM
/Brain 
Advanced 
Cancer 
      All Breast GU/GYN Lung/ 
GI/ 
H&N 
HAEM
/Brain 
Advanced 
Cancer 
 Total 
Global Quality 
of Life 
65.9  64.6 73.6 65.6 66.1 56.9  67.5 68.9 68.2 65.2 67.0 60.5  66.9 
Pain 27.8  4.2 18.9 30.6 21.8 44.9  24.1 21.1 27.3 29.7 15.8 43.5  25.4 
Abbreviations: GU = Genitourinary Cancer, GYN = Gynaecological Cancer, GI = Gastrointestinal Cancer, H&N = Head and Neck Cancer, 
HAEM = Haematological Malignancy 
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Figure 1: (a) Mean Global quality of life score (higher scores representing higher quality of life) and pain scores (higher scores representing higher pain)  (General German 
population data compared to data obtained by the present Austrian study); males;  
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Figure 1 (b) Mean Global quality of life score (higher scores representing higher quality of life) and pain scores (higher scores representing higher pain)  (General German 
population data compared to data obtained by the present Austrian study); females; 
 
